Landing

LinkedInFacebookTwitter

View ProSciento’s privacy policy here.

ON-DEMAND RECORDINGS NOW AVAILABLE

The 4th Annual NASH Roundtable Forum took place on November 18, 2021, with presentations and a Roundtable Member discussion focused on opportunities for collaboration bridging expertise from pharma, biotech, clinical research, and academic research. Forum moderators were Dr. Arun Sanyal, Dr. Julio Gutierrez, and Dr. Rohit Loomba.

You can now view a recording of the entire Roundtable Forum or the individual presentations.

Available Videos:

View a full video recording of the NASH Roundtable Forum

Approximately 2 hours

Click here to view Forum agenda

Individual Presentations Available:

Utilizing NASH PASS® Biobank for Biomarker Discovery and Translational Research

Presented by Julio Gutierrez, MD, Vice President of Clinical Research and Clinical Science, ProSciento, Inc. and Transplant Hepatologist at Scripps Health

Approximately 20 minutes

Collaborative Translational Research Opportunities Utilizing the NASH PASS® Biobank

Presented by Arun J. Sanyal, MD, Professor, Division of Gastroenterology, Hepatology and Nutrition, at Virginia Commonwealth University School of Medicine

Approximately 20 minutes

Biomarkers of Hepatic Fibrosis, Fibrogenesis, and Fibrosis Resolution

Presented by Morten Karsdal, PhD, Chief Executive Officer, Nordic Bioscience A/S

Approximately 15 minutes

Advances in Imaging Technologies for Fibrotic Diseases – A Look Forward

Presented by Lars Johansson, PhD, Chief Scientific Officer, Antaros Medical AB

Approximately 15 minutes


About the NASH Roundtable

The NASH Roundtable was established in 2018 as a platform to stimulate collaboration and build consensus towards validated biomarkers and endpoints and to support the development of effective and safe treatments. Today the Roundtable consists of distinguished physicians, researchers, and clinical development experts from three continents brought together by their common commitment to steward advances in science, clinical research, and therapeutics for fibrotic diseases. 

FacebookTwitterLinkedIn

ON-DEMAND RECORDINGS NOW AVAILABLE

The 4th Annual NASH Roundtable Forum took place on November 18, 2021, with presentations and a Roundtable Member discussion focused on opportunities for collaboration bridging expertise from pharma, biotech, clinical research, and academic research. Forum moderators were Dr. Arun Sanyal, Dr. Julio Gutierrez, and Dr. Rohit Loomba.

You can now view a recording of the entire Roundtable Forum or the individual presentations.

Available Videos:

View a full video recording of the NASH Roundtable Forum

Approximately 2 hours

Click here to view Forum agenda

Individual Presentations Available:

Utilizing NASH PASS® Biobank for Biomarker Discovery and Translational Research

Presented by Julio Gutierrez, MD, Vice President of Clinical Research and Clinical Science, ProSciento, Inc. and Transplant Hepatologist at Scripps Health

Approximately 20 minutes

Collaborative Translational Research Opportunities Utilizing the NASH PASS® Biobank

Presented by Arun J. Sanyal, MD, Professor, Division of Gastroenterology, Hepatology and Nutrition, at Virginia Commonwealth University School of Medicine

Approximately 20 minutes

Biomarkers of Hepatic Fibrosis, Fibrogenesis, and Fibrosis Resolution

Presented by Morten Karsdal, PhD, Chief Executive Officer, Nordic Bioscience A/S

Approximately 15 minutes

Advances in Imaging Technologies for Fibrotic Diseases – A Look Forward

Presented by Lars Johansson, PhD, Chief Scientific Officer, Antaros Medical AB

Approximately 15 minutes


About the NASH Roundtable

The NASH Roundtable was established in 2018 as a platform to stimulate collaboration and build consensus towards validated biomarkers and endpoints and to support the development of effective and safe treatments. Today the Roundtable consists of distinguished physicians, researchers, and clinical development experts from three continents brought together by their common commitment to steward advances in science, clinical research, and therapeutics for fibrotic diseases. 

FacebookTwitterLinkedIn